Review Article

miRNAs: The Key Regulator of COVID-19 Disease

Leyla Tahrani Hardin and Nan Xiao

Department of Biomedical Sciences at the Arthur A. Dugoni School of Dentistry, University of the Pacific, San Francisco, 94103 CA, USA

Correspondence should be addressed to Nan Xiao; nxiao@pacific.edu

Received 17 March 2022; Accepted 30 September 2022; Published 29 October 2022

Academic Editor: Prem Swaroop Yadav

Copyright © 2022 Leyla Tahrani Hardin and Nan Xiao. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

As many parts of the world continue to fight the innumerable waves of COVID-19 infection, SARS-CoV-2 continues to sculpt its antigenic determinants to enhance its virulence and evolvability. Several vaccines were developed and used around the world, and oral antiviral medications are being developed against SARS-CoV-2. However, studies showed that the virus is mutating in line with the antibody’s neutralization escape; thus, new therapeutic alternatives are solicited. We hereby review the key role that miRNAs can play as epigenetic mediators of the cross-talk between SARS-CoV-2 and the host cells. The limitations resulting from the “virus intelligence” to escape and antagonize the host miRNAs as well as the possible mechanisms that could be used in the viral evasion strategies are discussed. Lastly, we suggest new therapeutic approaches based on viral miRNAs.

1. Introduction

SARS-CoV-2, which causes the severe acute respiratory syndrome COVID-19, has spread rapidly after it emerged at the end of 2019, and it has made a striking impact on world health and economy [1–5]. The World Health Organization (WHO) announced a public health emergency of international concern on 30 January 2020 and a global pandemic on 11 March 2020. Acute respiratory distress syndrome (ARDS) was shown to be the most common cause of death during the COVID-19 pandemic [4, 6, 7].

SARS-CoV-2 is a positive-sense-single-stranded RNA virus, and like other coronaviruses, SARS-CoV-2 has four structural proteins, known as the S (spike), E (envelope), M (membrane), and N (nucleocapsid) proteins. The N protein holds the RNA genome, and the S, E, and M proteins together constitute the viral envelope [8]. The cell entry is mediated by the viral glycoprotein (S) that contains the receptor-binding domain (RBD) that is required for binding to the host cell receptors and other domains that are required for membrane fusion and intracellular trafficking [9]. The human lung and intestine epithelial cells express abundant angiotensin-converting enzyme 2 (ACE2), which is assured as the receptor of SARS-CoV-2 [10]. ACE2 is mainly expressed in lung alveolar type 2, liver cholangiocyte, colon colonocytes, esophagus keratinocytes, rectum and stomach epithelial cells, and kidney proximal tubules [11]. The infectivity and ACE2 expression are gradually decreased from the upper airway to the lower airway [12].

After infecting the host cells, SARS-CoV-2 showed ability to launch a cytokine storm and to overcome the host immune system [13, 14]. Immunoregulatory agents seemed to play a key role in fighting against COVID-19. With more reports and ongoing research revealing the possible viral pathological pathways and virus-host interactions, mechanism of therapeutic strategies could be better elucidated, and alternative treatment are being investigated. Numerous vaccines were developed such as DNA vaccine, inactivated vaccine, viral vector vaccine, and RNA vaccine. However, it seems crucial to investigate the genetic drivers for SARS-CoV-2 and determine the humoral and cell-based players to establish long-term endurance [15].

Eukaryotes evolve noncoding molecules, miRNAs, to suppress unwanted genetic materials and transcripts [16, 17]. Circulating miRNAs can be secreted or produced as a result of diverse biological processes, such as (i) passive secretion from...
injured or damaged cell by chronic inflammation or apoptosis, (ii) active secretion via cell-derived membrane vesicles such as microparticles (exosomes), and (iii) active secretion by formation of protein-miRNA complex (e.g., HDL and Ago2) [18, 19]. miRNAs are endogenous small RNAs that contains 18 to 25 nucleotides which regulate protein translation through binding to complementary nucleotide of target mRNA, typically in the 3′-untranslated region (UTR). They are involved in posttranscriptional gene repression or degradation and can attach to multiple targets. miRNAs are recognized to participate in biological development, cell differentiation, apoptosis, and many other physiological and pathological processes and serve thus as watchdogs in the cell [20–24]. Previous studies have reported that miRNAs encoding sequences form up to 1% of the human genome [25].

These small molecules showed a promising therapeutic potential in many viral diseases such as herpes simplex virus (HSV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and influenza [26–31]. miRNAs constitute attractive candidates to be developed as vaccines and antivirals [32]. Vaccination can still be the fastest and most cost-efficient strategy to achieve comprehensive immunity [15].

This paper reviews the mechanisms that could be implicated in the host-virus miRNA interplay. In particular, we discuss the possible epigenetic control-based therapies through the cross-talk between the viral miRNAs and host machinery.

## 2. miRNAs: The Epigenetic Key Regulators against COVID-19

miRNAs are noncoding small molecules that are used in numerous therapeutic strategies for several diseases. They control the posttranslational phase of miRNAs through blocking the translation or through degradation. Studies showed miRNAs may inhibit, induce, or serve as enhancers of gene expression, which expand future therapeutic ideas and help reveal the biopathological mechanisms of many diseases [33–36]. It was proposed that miRNAs control cell cycle and gene expression through (i) a direct translation of the pri-miRNAs into regulatory short peptides named miRNA-peptides (MiPEP) which enhance the accumulation of their corresponding mature miRNAs [37], (ii) protein binding and structure changing [38], (iii) activation of TLRs [39], (iv) upregulating protein expression [40], (v) mitochondrial targeting [41, 42], (vi) regulation of other miRNAs [43], and (vii) upregulation of the gene transcription [44].

The interaction between miRNAs and viral RNA is the key to understand the pathological mechanisms of viral infections [45, 46]. Viruses are dependent on the host cellular machinery for their replication; at the same time, this makes them an easy target of the host destructors like miRNAs [30]. In the case of COVID-19 disease, recent studies indicate that miRNAs tune down SARS-CoV-2 infection probably through the following mechanisms (Figure 1).

- (1) Posttranscriptional regulation of the expression of ACE2 and TMPRSS2
- (2) Downregulation of the ACE2 and TMPRSS2 gene expression
- (3) Binding to the viral genome and silencing or degrading it
- (4) Immunosuppression of cytokine storm through regulation of anti-inflammatory cytokine genes
- (5) Downregulation of the proinflammatory cytokine gene overexpression

### 2.1. Posttranscriptional Regulation of the Expression of ACE2 and TMPRSS2

The angiotensin-converting enzyme 2 (ACE2) transmembrane protein on host cells plays a crucial role in SARS-CoV-2 infection as a spike glycoprotein receptor [47]. The spike protein is also cleaved and activated by cell surface transmembrane protease serine 2 (TMPRSS2) to facilitate membrane fusion and entry [48, 49]. ACE2 is expressed in multiple human tissues, with the highest expression in the gastrointestinal tract, kidney, testis, and heart [50].

miRNAs represent an attractive protein-targeted therapy, exceptionally for the proteins that cannot be targeted by other small molecules [51]. Several miRNAs such as miR-200b-3p, miR-200c-3p, let-7c-5p, miR-98-5p, let-7 f-5p, miR-4500, and miR-27b may play a pivotal role in the deactivation of ACE2 or TMPRSS2 [22, 52]. miR-421 has also been previously identified as a potential ACE2 regulator [53]. A luciferase reporter system containing the 3′-UTR of ACE2 was exploited to identify the role of the miRNAs in ACE2 controlling; miR-421 and miR-483-3p showed to reduce ACE2 protein levels while the absence of the two miRNAs did not show to affect the ACE2 levels [53, 54]. According to Chen et al. [55], miR-421 and miR-483-3p controlled ACE2 expression through the translational mechanism rather the degradation of the transcripts. Also, the study of Kaur et al. [56] found that miR-214, miR-98, and miR-32 are able to repress TMPRSS2 with a high affinity to the binding sites on this protein especially miR-32.

### 2.2. Downregulation of the ACE2 and TMPRSS2 Gene Expression

Many miRNAs showed to regulate the ACE2 expression. The research of Hum et al. [57] showed a noticeable attention for miR-200 and miR-24 as they have been shown to correlate with the regulation of ACE2 and furin, respectively. Interestingly, studies highlighted that numerous miRNAs are involved in ACE2 expression such as miR-125b and miR-18, which directly target the 3′-UTR of ACE2 mRNA [58]. Sardar et al. [52] showed that considering the importance of cellular receptors, specifically ACE2, in SARS-CoV-2 infection, miR-27b regulates the ACE2 receptor. In another study, Chauhan et al. [22] reported that miR-200b-3p, miR-200c-3p, and miR-429 could act against ACE2 and let-7c-5p, miR-98-5p, and miR-4500 may regulate TMPRSS2. Moreover, Widiasta et al. [58] reported that miR-18 upregulated the ACE2 expression in nephropathy. Along the same line, Khan et al. [59] identified six miRNAs that could regulate ACE2 in humans, namely, miR-362-5p, miR-421, miR-500a-5p, miR-500b-5p, miR-3909, and miR-4766-5p.
2.3. Binding to the Viral Genome and Silencing It or Provoking Its Degradation. Several studies showed that miRNAs binding on viral RNA could stop the virus replication, and these miRNAs have a significant role in gene regulation via binding to a specific region in 3' untranslated region (3'UTR) or open reading frame (ORF) to degrade mRNA or block the translation process [60]. Mature miRNAs specifically recognize complementary sequences found in the 3'-UTRs of target mRNAs and can facilitate translational repression and/or provoke mRNA degradation [61].

Arisan et al. [62] found that miR-8066 could block the SARS-CoV-2 N gene, which encodes a basic RNA-binding protein that acts as both structural and nonstructural protein. So, targeting this gene can reduce or repress the assembly and production of viral particles. Moreover, Nersisyan et al. [6] reported that six miRNAs including miR-21-3p, miR-195-5p, miR-16-5p, miR-3065-5p, miR-424-5p, and miR-421 are potentially regulating all human coronaviruses including SARS-CoV-2 through direct binding to the viral genome. miR-21-3p showed the highest binding level to the human coronavirus genome. miR-5047 inhibits the cleavage of the ORF1a/b polyprotein gene [63], miR-1307-3p can also target human gene expression responsible for survival and proliferation (BCL2, PI3K pathway activators), clathrin-dependent endocytosis (AP2, PI3K), and exocytosis (Actin) associated with virus cell entry and spread [64].

Chauhan et al. [22], through a bioinformatic analysis, determined miRNAs that target SARS-CoV-2 viral genes (e.g., repressing the spike protein gene) avoiding the viral binding on the host cell receptors. The imperfect attachment will result in an inhibition of the translation, while the perfect attachment will result in degradation of the mRNA [65]. In another bioinformatic study, Ivashchenko et al. [66] reported that miRNA-5197-3p can bind to SARS-CoV-2 genomic RNA and inhibit any gene expression modification in human cells. Along the same line, a computational study performed by Fulzele et al. [3] demonstrated that 873 human miRNAs were involved in binding and inhibiting SARS-CoV-2, and 558 of them targeted the virus genome. The highest binding score was observed with miR-15a-5p, miR-15b-5p, miR-30b-5p, miR-409-3p, miR-505-3p, and miR-548d-3p.

Ivashchenko and colleagues [66] identified human miRNAs that may alter the expression of SARS-CoV-2 genome. Their goal was to design a set of miRNAs that would specifically bind to the coronavirus genome to degrade it; they found miR-5197-3p endowed with the highest affinity to bind to SARS-CoV-2 genome. In addition, miRNAs can target virus genes and adjust their expression by degrading mRNA or deactivating the translation [3, 67]. Bertolozi et al. [68] suggest that the miR-1207-5p family may bind to SARS-CoV-2 viral genome resulting in a deregulation of CSF-1, which may promote an inflammation in COVID-19 patients. According to Saçar Demirci and Adan
[69], who investigated the plausible SARS-CoV-2 genes by host miRNAs, the results showed that except envelope (E) protein and ORF6, all viral genes (S, M, N, ORF1ab, ORF3a, ORF8, ORF7a, and ORF10) are targeted by multiple human miRNAs. An in silico study by Jafarinejad-Farsangi et al. [70] showed that miR-29 family of miRNAs was found to target 11 sites on SARS-CoV-2 genome. An experimental design consisted of luciferase reporter-plasmids carrying viral target sequences (pSpike) cotransfected with miRNA mimics in A549 cell line. The results showed an inhibition ranging from 60% (miR-30c and miR-15b) to more than 80% (miR-219a and miR-29a) [71].

2.4. Immunosuppression of Cytokine Storm through Regulation of Anti-Inflammatory Cytokine Genes. miRNAs have been shown to play a fundamental role in regulating the innate and adaptive immune response through several processes such as the maturation, secretion, and proliferation of T cells and B cells [72]. Nepotchatchkli et al. [73] reported that miR-127-3p could regulate the expression of the BCL6 gene, resulting in a suppression of IL-10 expression, which has a crucial role in immune reaction alleviation. In addition, Yousef et al. [74] discussed whether the host miRNAs can act either by regulating the host immune response, encoding for cytokine genes and changing the cell communication, or by directly targeting viral transcripts, degrading or silencing them. Schultz et al. [75] introduced more than two hundred miRNAs responsible for alleviating the cytokine exacerbation and three hundred miRNAs may at the same time inhibit the inflammatory agents and the cell death genes, hence preventing site injury. It has been shown that miRNAs play a crucial role in regulating the function of DCs, epithelial cells, monocytes, granulocytes, NK cells, and macrophages which are the principal actors in the innate immunity [76].

The analysis of differentially expressed genes targeted by host miRNAs demonstrated that 329 genes were upregulated and 452 genes were downregulated in the lung tissues from two postmortem men infected with SARS-CoV-2 compared to two healthy controls. Moreover, the results of enrichment analysis revealed that these genes were associated with the cytokine-mediated signaling pathway [70]. A previous study of Matsui et al. [77] showed that miRNAs can be translocated to the nucleus by importin 8 with AGO1 or AGO2; they determined that miR-589-AGO2 entered the nucleus to enhance the cyclooxygenase-2 (COX2) transcription. This mechanism could help explain how SARS-COV-2 is modulating the cytokine expression and open new therapeutic avenues.

A list of COVID-19-associated-miRNAs involved in immune response can be found in Table 1.

2.5. Downregulation of the Proinflammatory Cytokine Gene Overexpression. It was reported that in addition to the anti-inflammatory cytokines, the expression of proinflammatory cytokines is also controlled by miRNAs [78]. miRNA-155 increased in human cell lines infected with SARS-CoV-2 (Vero E6, Calu-3, and Caco-2) [79]. The serum concentration of miR-155 was significantly increased in COVID-19 patients compared to healthy controls [80]. This miRNA was associated with many viral infections [81, 82] and has been demonstrated to be an immune cell differentiation modulator [83]. Another study correlated the expression of miR-125b, miR-138, miR-199a, and miR-21 with the increase of TNF-α, IL-1β, and IL-6 [60]. In addition miR-146a and miR-146b were found to correlate with the increase of IL-8 in the acute respiratory distress syndrome and COPD [60, 84]. miR-323a-5p inhibits the translation of the ORF1a/b polyprotein gene [69] and miR-922 regulates PDCD1, which was found upregulated in SARS-CoV-2-infected samples and associated with T cell receptor signaling pathway, adaptive immune system regulation, T cell activation, leukocyte activation, and cell activation [85]. miR-326 showed correlation with leukocyte aggregation, defense response to fungus, neutrophil chemotaxis, granulocyte chemotaxis, neutrophil migration, regulation of immune system process, and cytokine-mediated signaling pathway [85, 86]. Five highly expressed miRNAs were identified in the placental MSC-EV, miR-92a-3p, miR-26a-5p, miR-23a-3p, miR-103a-3p, and miR-181a-5p, and showed to bind to the conserved sequence in SARS-CoV-2 genome and modulate the immune response [87].

On the other hand, Arisan et al. [62] found seven sequences in the SARS-CoV-2 mRNA that are highly similar to human miRNAs and they determined the probable molecular pathways associated with these miRNAs in the pathogenesis of COVID-19. Five of the seven miRNAs (miR-8066, miR-3934-3p, miR-1307-3p, miR-1468-5p, and miR-3691-3p) were implicated in the TGF-β signaling pathway. TGF-β is a mediator associated with lung development and homeostasis, and it also plays a role in the immunity, survival, migration, and apoptosis of host cells [88]. In addition, these miRNAs showed to be involved in viral entry and invasion, cytokine synthesis, and other disease complications such as pulmonary hypertension and cardiac fibrosis [89].

3. Ability of SARS-CoV-2 Escaping the Host Immune System through miRNAs

As discussed above, miRNAs are implicated in the host-pathogen interplay through silencing viral genes to fight against COVID-19. However, virus can develop new mechanisms to escape host antiviral response and to ensure its propagation [90]. Many studies reported that both virus and host encode miRNAs [91–95], and there are many types of viral miRNA-host mRNA interactions [30, 61]. Over the last two decades, hundreds of virus-encoded miRNAs have been identified [96]. Viral miRNAs aim to induce the degradation of host miRNAs, to inhibit or regulate their expression, and to target a large number of host genes involved in regulating cell proliferation, apoptosis, and host immunity [67, 97–99, 99].

The latest research indicated that SARS-CoV-2 could escape the attack of host immune system through miRNAs as well. The probable mechanisms are (Figure 2) as follows:

(1) Inhibition of the host miRNAs by sponge forming and degradation
Table 1: COVID-19-associated miRNAs involved in immune response.

| miRNAs      | Role in the immune response                                                                 | miRNA expression | References          |
|-------------|---------------------------------------------------------------------------------------------|------------------|---------------------|
| miR-15a-5p  | Binding to SARS-CoV-2-encoded transcripts involved in immunity enhancing                     | Upregulated      | [89, 184, 185]      |
| miR-15b     | Positively correlated with inflammation Regulating the host immune response                  | Upregulated      | [140, 186, 187]     |
| miR-17-5p   | Having actual target sites in SARS-CoV-2 and in inflammation response, role not well known   | Downregulated    | [3]                 |
| miR-21      | Regulating inflammatory response Correlated with macrophage numbers and with MCP-1 protein expression in the bronchoalveolar lavage (BAL) supernatant 27 binding sites on SARS-CoV-2 genome with the highest target scores | Upregulated      | [80, 141, 188, 189] |
| miR-23a-3p  | Binding to the complemented sequence which led to the recovery of the cytopathic effects Related to cytokine–cytokine receptor interactions, TNF, NF-κB, chemokines, Toll-like receptors, and the Jak–STAT signaling pathway | Not reported      | [87]                 |
| miR-25-3p   | Having strong binding potential against TMPRSS2 in COVID-19 disease Implicated in the SARS-CoV-2 talk with host cell Downregulated in COPD | Downregulated    | [74, 190–193]       |
| miR-29a     | Identified in COVID-19 infection Anti-inflammatory in cancer and other diseases               | Upregulated      | [70, 139, 194]      |
| miR-31-5p   | Mediating inflammatory signaling                                                            | Downregulated    | [129, 131, 140, 195]|
| miR-98      | Negatively correlated with inflammatory cytokines                                           | Downregulated    | [196, 197]          |
| miR-99a-5p  | Targeting proinflammatory genes                                                             | Downregulated    | [140, 198]          |
| miR-124     | Targeting the 3′-UTR binding sites on IL-6 gene in COVID-19 disease Suppressing LPS-induced p65 expression and cell apoptosis Decreasing the levels of inflammation and pulmonary injury | Not reported      | [199, 200]          |
| miR-125b    | Binding to the 3′-UTR region of TNF and IFN and also to the 3′-UTR of factor XIII gene       | Downregulated    | [75, 193]           |
| miR-142-3p, miR-142-5p | Promoting inflammatory process Downregulated in COVID-19 infection | Downregulated    | [140, 188]          |
| miR-146a-5p | Acting as biomarker and providing a molecular link between inflammation and the COVID-19 infection | Downregulated    | [140, 201, 202]     |
| miR-149-3p  | Suppressing hepatic inflammatory response through antagonizing the STAT3 signaling pathway Not reported | Not reported      | [1]                 |
| miR-150     | Predicted to have binding sites in the SARS-CoV-2 genome Alleviated LPS-induced inflammatory response and apoptosis A target in the development of anti-inflammation and antiapoptosis drugs for sepsis treatment | Downregulated    | [3, 63, 69, 160, 193, 203] |
| miR-155     | Reducing proinflammatory cytokines Increased antiviral and anti-inflammatory cytokine responses in the lungs | Upregulated      | [63, 138]           |
| miR-181a    | Inhibiting secretion of proinflammatory factors especially the increase in TNF-α            | Downregulated    | [140, 204]          |
| miR-195     | Promoting resolution of inflammation                                                      | Upregulated      | [131, 196, 205, 206]|
| miR-200 family | Members of this family are proinflammatory as well as anti-inflammatory Regulating ACE2 (virus entry) in respiratory cells in COVID-19 disease | Upregulated      | [207–209]          |
| miR-320 family | Significantly correlated with CRP, IL-6, and D-dimer levels                                | Downregulated    | [210]               |
| miR-342-5p  | Targeting N (nucleocapsid) protein gene in SARS-CoV-2 infection Promoting inflammatory activation of macrophages | Upregulated      | [69, 211]          |
miRNAs, which are strongly likely to bind with the SARS-CoV-2 genome, including SARS-CoV-2. The viral RNA may act as many miR-16 binding sites in human coronavirus HCoV and activation [68]. Another study reported that there are to CSF1 release leading to enhanced macrophage recruitment the cell may sequestrate miR-1207-5p therefore contributing regulatory machine by sequestering the selected miRNAs.

miR-16 is known by its role in triggering apoptosis via downregulating survival factor BCL2 [101]. It gets in the host [100]. miR-16 is known by its role in trigging its abundance in infected cells resulting in a decrease of its tar-

tem and to promote the viral cycle. The high potential miRNA SARS-CoV-2 mRNAs could regulate host

CoV-2 genome and are expressed in diverse respiratory epithelial and immune cells, were identified and some researchers suggest that there is a possibility that the SARS-CoV-2 genome may sequester cellular miRNAs during pathogenesis, especially in high copy numbers in infected cells [102]. Moreover, the study of the potential role of the 28 miRNAs, which were uniquely specific for SARS-CoV-2, showed that the virus by its potential reduction of the host’s miRNA pool may modulate specific gene expression to suppress immunity or prevent activation of unfolded protein response- (UPR-) related apoptosis and promote infected cell survival and thus continue its replication cycle [1]. A study using bioinformatic approaches showed that the SARS-CoV-2 virus can serve as a “sponge” for human miRNAs such as miR-374a-5p, let-7f-1-3p, miR-374a-3p, miR-588d-3p, and miR-23b-3p [103]. miR-302c-5p, which is expected to be sponged by the SARS-CoV-2 genome, can potentially lead to increased ACE2 expression which has already been reported to be associated with severe COVID-19 cases [103, 104].

3.1. Inhibition of the Host miRNAs by Sponge Forming and Degradation. SARS-CoV-2 mRNAs could regulate host miRNA levels by acting as sponges to evade the immune system and to promote the viral cycle. The high potential miRNA binding sites could offer a very effective defense by reducing the cellular miRNA levels during the infection [1]. The viral sequence, once expressed, can interact with the host’s miRNA regulatory machine by sequestering the selected miRNAs.

It is reported that the high concentration of viral RNA in the cell may sequestrate miR-1207-5p therefore contributing to CSF1 release leading to enhanced macrophage recruitment and activation [68]. Another study reported that there are many miR-16 binding sites in human coronavirus HCoV genomes, including SARS-CoV-2. The viral RNA may act as a “sponge” to sequester miR-16 [57], consequently decreasing its abundance in infected cells resulting in a decrease of its targets in the host [100]. miR-16 is known by its role in trigging apoptosis via downregulating survival factor BCL2 [101].

Along the same line, a total of 14 high-confidence mature miRNAs, which are strongly likely to bind with the SARS-CoV-2 genome and are expressed in diverse respiratory epithelial and immune cells, were identified and some researchers suggest that there is a possibility that the SARS-CoV-2 genome may sequester cellular miRNAs during pathogenesis, especially in high copy numbers in infected cells [102]. Moreover, the study of the potential role of the 28 miRNAs, which were uniquely specific for SARS-CoV-2, showed that the virus by its potential reduction of the host’s miRNA pool may modulate specific gene expression to suppress immunity or prevent activation of unfolded protein response- (UPR-) related apoptosis and promote infected cell survival and thus continue its replication cycle [1]. A study using bioinformatic approaches showed that the SARS-CoV-2 virus can serve as a “sponge” for human miRNAs such as miR-374a-5p, let-7f-1-3p, miR-374a-3p, miR-588d-3p, and miR-23b-3p [103]. miR-302c-5p, which is expected to be sponged by the SARS-CoV-2 genome, can potentially lead to increased ACE2 expression which has already been reported to be associated with severe COVID-19 cases [103, 104].

3.2. Mutation in Viral Genome Binding Sites of the Host miRNAs. Another way used by SARS-CoV-2 to evade the immune system and to propagate is mutation. It was shown that mutation in RNA viruses is quite frequent because of the RNA-dependent RNA polymerase’s inadequate proof-reading activity [105, 106]. SARS-CoV-2 could change the binding sites of host miRNAs through mutations. The pathogenicity of the virus can be deeply affected by mutations, e.g., through modification of the RNA secondary structure or creating new binding sites for host miRNAs [107].

A study of Hosseini Rad SM and McLellan [108] identified a lost binding site for miR-197-5p, which was located in the nonstructural protein 3 (Nsp3) sequence. Nsp3 is the largest protein encoded by the coronavirus genome and plays an essential role in replication and transcription. The Nsp3 synonymous C3037U mutation could impact viral fitness. Van Dorp et al. [109] demonstrated that the Nsp3 C3037U mutation was
significantly associated with virus transmission. miR-197-5p is overexpressed in patients with cardiovascular disease that demonstrate an increased susceptibility to SARS-CoV-2 infection [110]. A number of researches showed that miR-197-5p was associated with defense mechanisms against certain viruses such as HBV, HCV, and H7N9 [111–113]. The loss of miR-197-5p-mediated defense against SARS-CoV-2 may be related to the increased mortality noted in this patient group [7].

Chan et al. [114] reported that mutations in SARS-CoV-2 3'-UTR lead to virus escape from the host immune system. In the study of Liu et al. [107], both miR-939-5p and miR-146b-3p, which were involved in maintaining homeostasis by decreasing inflammatory response, were predicted to be incapable of binding to the mutant-type genome. Park et al. [115] found that most sites of the viral genome that bind to 3'-UTR miRNAs are conserved and rarely mutated, whereas the binding sites of miR-181a-5p, miR-92a-3p, miR-92b-3p, and miR-25-3p were mutated in the SARS-CoV-2 genome from Australian samples.

3.3. Antagonizing the Host miRNA Biogenesis Pathway. Several viruses showed to hijack the host miRNA biosynthesis through viral proteins such as Ebola’s VP35 [116] and HCV’s core protein [117]. There is possibility that SARS-CoV-2 could use the same evasion strategy. Many RNA viruses showed to inhibit the maturation of the host miRNAs through argonaute (AGO) effectors [91]. The 2b protein of the cucumber mosaic virus (CMV) appeared to be a repression factor of AGO1 slicer function [118], while the p19 protein of the tomato bushy stunt virus (TBSV) showed to impede the activity of RNA-induced silencing complex (RISC) loading activity through binding to small double-stranded RNAs [119]. It was reported that Dicer, which represents the most critical regulator of the biogenesis of miRNA and small interfering RNA [120], could be sequestrated by the noncoding (nc) subgenomic flavivirus RNA [121]. According to Arora et al. [122], the receptors of Ddx58, which contributes to the miRNA biogenesis and mRNA splicing, showed to be highly upregulated in COVID-19 disease. SARS-CoV-2 hijacks Ddx58 to foster its replication [60, 122]. Bartoszewski et al. [1] identified 10 pre-miRNA sequences in the SARS-CoV-2 RNA sequence that could potentially interfere the human miRNA biogenesis, hypothesizing that maybe SARS-CoV-2 encode in its own pre-miRNA sequences that could mature in human cells. Arisan

Figure 2: Probable SARS-CoV-2 escape strategies through miRNAs. SARS-CoV-2 can escape the immune response through strategies: 1—inhibition of the host miRNAs by sponge forming and degradation, 2—mutation in viral genome binding sites of the host miRNAs, 3—antagonizing the host miRNA biogenesis pathway, 4—altering the host miRNA network activity, 5—encoding cytokines and TMPRSS2 genes, 6—increasing miRNA binding sites, silent viral replication, and avoiding the immune system, 7—competition between RNA-binding proteins (RBP) and miRNAs, 8—mirroring the host miRNAs, and 9—targeting RNA-directed miRNA degradation (TDMD). Abbreviations: ACE2: angiotensin-converting enzyme; TMPRSS2: transmembrane protease serine 2; AGO: argonaute; Dicer; RBP: RNA-binding protein; RISC: RNA-induced silencing complex.
et al. [62] found in their predictive study that SARS-CoV-2 genome reveals RNA structures (miRNAs), which could be conceivable Drosha and Dicer substrates. However, another RNA virus, the influenza virus, replicates inside the host nucleus and utilizes the nuclear miRNA processing factor Drosha to express viral miRNAs [67, 123]. So, the RNA molecules are accessible to the miRNA biogenesis machinery in the nuclei. SARS-CoV-2 could use this alternative to synthesize its viral miRNAs.

3.4. Altering the Host miRNA Network Activity. Viruses have been shown to change the host miRNA expression landscape, and they are able to bind directly to host miRNAs or to use them for their needs to stabilize genome, to propagate, and to maintain diseases [46, 57, 61].

The host miRNAs can be dual hatted and can sometimes participate in the viral escape by modifying host immune mediators [91]. Khan et al. [59] reported that during SARS-CoV-2 infection host miRNAs may downregulate the signaling of different TLRs, which play a fundamental stimulatory role in inducing the host antiviral activity (i.e., secretion of interferons and other inflammatory cytokines). A recent in silico study showed that six host miRNAs (hsa-miR-32-5p, hsa-miR-98-3p, hsa-miR-214-3p, hsa-miR-421, hsa-miR-423-3p, and hsa-miR-1246) can target ACE2 and TMPRSS2 and the number of binding sites of hsa-miR-98-3p and hsa-miR-423-3p was the highest (a match of 6 nucleotides) [124]. These miRNAs were found to increase in critical COVID-19 patients. In addition, a functional analysis showed that the target genes are involved in the viral process, including viral RNA replication and viral entry into the host nucleus or regulation of the viral genome replication [124].

In the study of Saçar Demirci and Adan [69], a total of 1367 human genes seem to be targeted by SARS-CoV-2 viral miRNAs. Some of the predicted targets of these viral miRNAs in human genes have roles in transcription. The eukaryotic transcription regulators would be the most important targets of 18 SARS-CoV-2-derived mature miRNAs; these targets are all involved in transcription process [69]. Mostly viral miRNAs have shown their role in overall pathogenesis by regulating host genes [125]. The findings of an in silico study have shown an analogy between the SARS CoV2 genome and regulatory host miRNA such as miR8066, miR5197, miR3611, miR3934-3p, miR1307-3p, miR3691-3p, and miR1468-5p [59].

SARS-CoV-2 hijacks the miRNA expression for an immunomodulatory activity; the virus provokes the cytokine storm to escape the immune system and upregulate or downregulate the miRNA expression, which lead to maladaptive immune system while maintaining active replication [126, 127]. It was found that 35 miRNAs were upregulated and 38 miRNAs were downregulated in COVID-19 patients compared to healthy donor. Notably, miR-6501-5p and miR-618 expression levels were 1.5-fold higher and miR-627-5p 2.3-fold lower in COVID-19 patients than in healthy donors. The expression of miR-183-5p, miR-627-5p, and miR-144-3p was also reduced [128]. Another study reported that 55 miRNAs were differentially expressed in the plasma of COVID-19 patients compared to healthy controls. 20 miRNAs were upregulated and 30 were downregulated. The most strongly upregulated miRNA was miR-31-5p, which was reported as an important factor in inflammatory disorders [129, 130], while the most downregulated miRNAs were miR-1275, miR-3617-5p, and miR-500b-3p [131]. The associated transcription factors of miRNAs miR-429 and miR-1286 were upregulated, and their target genes were downregulated, suggesting they might have some roles in this host-virus interactions [132]. In an in silico-based study, miRNAs were shown to act in synergy, and it was demonstrated that SARS-CoV-2 can alter the miRNA network activity and reroute it for its advantage [74]. The dysregulation of miR-1207-5p-target genes during SARS-CoV-2 infection may lead to uncontrolled inflammation in most severe COVID-19 cases [68]. Several other researches showed that miR-1207-5p is involved in contributing to virus propagation and especially to the virus reviving from latency phase [133]. Moreover, Arisan et al. detected mutations in miR-1307 and miR-8066, miR-129-2-3p, and miR-129-2-3p. These three miRNAs are potentially involved in pathways related to SARS-CoV-2 infection and host defense such as mucin type O-glycan biosynthesis, TGF-signaling pathway, amphetamine addiction, cytokine-cytokine receptor interaction, and nicotinate-nicotinamide metabolism [62].

Based on the available evidence, it is reasonable to hypothesize that SARS-CoV-2 may change the host’s miRNAome to create a proviral microenvironment for its own replication and propagation, through modifying host miRNAs and consequently altering cellular machineries during infection. Moreover, the viral-derived miRNAs are one of many options that SARS-CoV-2 uses to escape the host immune system through interfering host gene expression, blocking or inducing host miRNAs.

3.5. SARS-CoV-2 miRNAs and Proteins Are Involved in Encoding Cytokines and TMPRSS2 Genes. A computational study performed by Liu et al. [134] showed that SARS-CoV-2-derived miR-147-3p potentially could enhance the expression of TMPRSS2, which is an entry ACE2 receptor enhancer, with the function of strengthening SARS-CoV-2 infection in the gut. Moreover, Liu et al. [134] reported that 11 SARS-CoV-2-derived miRNAs were found to be bound to the 5′-UTR of 13 target genes, including the binding between a virus-encoded miRNA MR385-3p and TGFBR3 (transforming growth factor beta receptor 3), which is known to be implicated in the innate and adaptive immune response [135]. Gene ontology (GO) and pathway functional enrichment of the targeted genes by the SARS-CoV-2 miRNAs revealed different pathways implicated in several immune signaling, such as T cell-mediated immunity, autophagy, TGF-β signaling, mTOR signaling, and TNF-α signaling which are particularly targeted by SARS-CoV-2 [59]. Six SARS-CoV-2 miRNAs (SARS-CoV-mir-1-5p, SARS-CoV-mir-2-5p, SARS-CoV-mir-3-5p, SARS-CoV-mir-4-5p, SARS-CoV-mir-5-5p, and SARS-CoV-mir-6-5p) were found to target immune-related genes that play an important role in immune pathways like TNF and...
chemokine signaling pathways [136]. Another study determined that miR-8066, 5197-3p, 4778-3p, and 6864-5p sequence is found on SARS-CoV-2 genomes. These SARS-CoV-2-mediated alterations of miRNAs may act as autocrine or paracrine agonists of host cells to trigger pro-inflammatory cytokines, due to their increased NF-KB activity [62].

Viruses-encoded proteins can inhibit the upregulation of host miRNAs which are triggered upon viral infection to suppress the innate immune response. Zhai et al. [137] identified a Borna virus-encoded protein which is able to suppress the expression of miR-155, which is implicated in innate immune responses. The suppression of miR-155 showed to attenuate lung cytokine storm in mice infected with SARS-CoV-2 [138, 139]; here, we suggest that miR-155 could be regulated by viral proteins as well. Along the same line, miR-146a, miR-21, and miR-142 were found in COVID-19 patients triggering the inflammatory machinery through activating MAPK and NF-KB signaling [140]. It was identified that restricting miR-21 or miR-142 would promote multiple cascading reactions and activation of the JAK-STAT cell signaling circuit, resulting in proinflammatory status advancements [125]. Trobaugh and Klimstra [46] suggested that viral protein-mediated changes in miRNA expression may occur through an indirect mechanism governed by viral inhibition of the innate immune response rather than a direct interaction between the viral protein and the transcription factors that regulate miRNA expression.

3.6. Increasing Host miRNA Binding Sites, Silencing Viral Replication, and Avoiding the Immune System. Nersisyan et al. [6] reported that host miRNAs had dozens of binding regions on SARS-CoV-2. miR-16-5p, miR-195-5p, and miR-424-5p viral binding sites showed to be highly conserved across human coronaviruses and their strains. Along the same line, miR-29 family (miR-29a, miR-29b, and miR-29c) was shown to have the most binding sites (11 sites) on SARS-CoV-2 and eight binding sites for miR-29a-3p, miR-29c-3p, miR-21-3p, miR-761, and miR-3130-3p [70]. Increasing the host miRNA binding sites could be explained by the fact that SARS-CoV-2 shuts down its own viral cycle rate for evading perception and destruction by the host immune system [141]. Such behavior was highlighted, for example, in the case of eastern equine encephalitis virus (EEEV); miR-142-3p binds to EEEV genome and represses the viral translation and replication only in myeloid cells likely limiting both innate and acquired immune responses to EEEV [142]. Also, a previous study showed that the viral miR-BART22, which is encoded by Epstein-Barr virus (EBV), modulates the latent membrane protein 2A (LMP2A) expression. This may facilitate the escape of EBV-infected cells from host immune surveillance [143].

Similarly, SARS-CoV-2 showed to alter the circulating levels of miR-21 and miR-16, which are known to suppress the secretion and expression of TNF-α and IL-6 mRNA, activation of macrophages, and proliferation of smooth muscle cells in normal cellular environment [63, 144, 145]. Bautista-Becerril et al. [145] explained this by the binding of these miRNAs to the virus receptors or its target mRNAs. Although miRNAs canonically serve as posttranscriptional repressors of cellular mRNAs, they may have unconventional roles as activators as, for example, in the case of the miR-122: HCV relationship. A possible explanation is that miR-122 binds to the SARS-CoV-2 RNA genome in the same way that it binds with the HCV genome, and the host-virus RNA-RNA interactions ease viral cycle. There is possibility that similar mechanism might apply in COVID-19 progression during which some host miRNAs turn out to be a positive cofactor of SARS-CoV-2.

3.7. Competition between RNA-Binding Proteins (RBP) and miRNAs. In addition, the 50 and 30 untranslated regions (UTRs) of the SARS-CoV-2 RNA contain binding sites for cellular miRNAs and RNA-binding proteins (RBPs) [89]. The host miRNAs target the viral RNA, generally leading to RNA degradation, and the translation of viral proteins can be induced by the binding of RNA-binding proteins (RBPs) such as CUG-binding protein (CUG-BP) and trans- active response DNA-binding protein (TARDBP) [146]. For example, in a SARS-CoV-2 variant, a mutation happened in the binding site for CUG-BP and turned it into a TARDBP binding site via a change of “C” to “U” on position 241; consequently, viral infectivity and mortality increased [147]. Mukherjee and Goswami [146] reported miR-34b-5p bond RNA-binding motif single-stranded-interacting protein 3 (RBMS3) at binding sites for host miRNA to stabilize this RBP, avoiding miRNA strike and RISC-induced RNA decomposition. In addition, miRNA binding might be prevented by a specific nucleotide modification in an overlapping binding site, while RBP binding remains possible; an example of this scenario is seen in miR-9-5p and HNRNP A1 [146].

RNA-protein interactions showed to block regions of the virus genome, making them unreachable for host cellular miRNA targeting, creating a competitive site binding between miRNAs and RNA-binding proteins [102, 148]. We suggest the presence of the same mechanism for SARS-CoV-2 involving the virus-derived miRNAs and RBP-binding proteins.

3.8. Viral miRNAs Mirror the Host miRNAs. SARS-CoV-2 showed to secrete identical miRNAs to the human miRNAs. Another mechanism that could be implicated in the viral escape from the regulation of host miRNAs is mirroring the host army. According to Henzinger et al. [89], SARS-CoV-2 could mirror host miRNAs through the expression of identical viral miRNAs.

It has been reported that virus-encoded miRNAs share seed region, which is the binding determinant region [149], with host miRNAs, and this was observed, at least, for three viruses: Kaposi’s sarcoma-associated herpesvirus (KSHV), Marek’s disease virus 1 (MDV1), and bovine leukemia virus (BLV). These viral miRNAs have been shown to negatively regulate transcripts via the same target docking sites as their counterpart host miRNAs [150]. Mimicking a host miRNA allows a viral miRNA to potentially regulate hundreds of transcripts that have evolved target sites for a particular host miRNA, as the case of the seed sharing between the KSHV-encoded miR-K11 and
human miR-155 which was associated with the downregulation of a common set of host mRNA transcripts [151, 152]. miR-155 showed to have an oncogenic role in many diseases [153–155]; also, it showed to play a pivotal role in the immune response [156–160]. Moreover, miR-155 appeared to play a role in the cell differentiation of B cells, T cells, and macrophages [93]. Many studies reported the high miR-155 expression in COVID-19 patients [79, 138, 139]. SARS-CoV-2 might also evolve mimics of host miRNAs to attain the memory B and T cell populations found during a latent infection.

3.9. Target RNA-Directed miRNA Degradation (TDMD) Pathway. Another phenomenon observed for the coronavirus's infection is the TDMD, where the repression of the host miRNAs does not engage the miRNA gene transcription or the miRNA biogenesis; however, the mature miRNAs, after they are loaded into argonaute (AGO), bind to a highly complementary viral RNA region by a mechanism involving nucleotide addition, tailing, trimming, and decay [161–163]. The computational study of human miRNAs and coronavirus RNA interaction of Nersisyan et al. [141] showed that the expression of miR-21-3p in mouse lungs increased 8-fold upon SARS-CoV infection, while miR-21-5p (the "guide" strand of the same pre-miRNA hairpin) exhibited only 3-fold increase. They hypothesized that the unsimilar upregulation of miR-21 arms could be due to SARS-CoV-2 RNA triggering of the host miRNA degradation. miR-21-3p was previously implicated in several RNA virus infections such as influenza A virus [164], Chandipura virus [165], and Coxsackievirus [166].

4. Viral miRNAs as Therapeutic Approaches

RNA viruses have been showed high mutation rate which is a million times higher than the host mutation rate [167]. Considering that coronaviruses are rapidly evolving in humans, this enables them to escape therapeutic therapies and vaccine-induced immunity [168]. A new study demonstrated that SARS-CoV-2 receptor-binding domain (RBD) can tolerate large numbers of simultaneous mutations and evade antibody neutralization through an N-linked glycan [169]. With this continuous fast viral evolution, it will not be surprising that highly antibody-resistant strain emerges.

Most of the previous studies were focusing on miRNAs and viral proteins as therapeutic alternatives or as vaccine models. Based on the crucial role that miRNAs can play in COVID-19 infection, using miRNAs as targets may represent the dawn of a new therapeutic era. Compared to targeting host miRNAs, which are involved in much more complexed physiological pathways, targeting viral miRNAs would be more achievable.

Like their hosts, most pathogens, such as viruses, also encode miRNAs to promote their survival [127, 170]. Mature viral miRNAs can be targeted using antisense oligonucleotides, known as antimiRs [171], miRNA sponges, ribozymes, and CRISPR technique. Some probable mechanisms are (Figure 3) as follows:

1. Inhibition of the viral miRNA function through antimiR

2. Blocking multiple viral miRNAs through miRNA sponge

3. Cleavage of viral miRNAs with ribozyme technique

4. Deletion of base pairs, disrupting the original miRNA sequence, and causing its inactivation by CRISPR technique

A miRNA antagonist is usually introduced as a chemically modified miRNA which is known as antimiR or antagomiR that could complementarily bind to the mature miRNA strand. Thus far, scientists developed various chemical structures of antimiR oligonucleotides with the goal to maximize their binding affinity, stability, and in vivo delivery [172]. A complementary strand to a viral miRNA could be constructed based on the highly conserved viral miRNA sequence, inserted to a vector with a sequence of RNA-binding proteins to provoke viral miRNA degradation. Several antimiRs were developed as treatments for viral diseases; miravirsen, which targets miR-122, was used for treatment of hepatitis C virus to reduce liver and plasma viral titers [173], and anti-EBV-miR-BART7-3p inhibits the tumorigenicity of Epstein-Barr virus (EBV) in mouse infected cells [174].

miRNA sponges are plasmid constructs which use a transgenic overexpression of RNA molecules containing multiple high-affinity miRNA complementary binding sites to a miRNA of interest to block the function of a given miRNA or a miRNA family [100]. These transcripts can efficiently sequester specific miRNAs, preventing their binding to endogenous target genes [175]. RNA oligonucleotides containing many viral miRNA binding sites could be used as a fish trap in order to sequester them.

Moreover, the viral miRNAs could be modulated through synthetic ribozymes, which target the highly conserved regions in viral miRNAs implicated in virus replication, assembly, and release processes. It is possible to exploit the site-specific cleavage ability of hammerhead ribozymes to design synthetic ribozymes and establish that they can cleave viral miRNAs [176].

Along the same line, many studies demonstrated that cloning CRISPR/cas9 constructs with single-guide RNAs specifically targeting biogenesis processing sites of selected miRNAs can robustly and specifically reduce the expression of these miRNAs [177–179]. The CRISPR/cas9 technology showed be effective in modifying miRNA precursor structure and disrupting its processing [180].

Several viral miRNAs were identified by recent studies, and they interestingly represent therapeutic candidates particularly those playing roles in viral replication.

There have been reports on viral miRNAs that could be the potential targets. miR-7a is a viral miRNA which hijacks the host miRNA machinery and antagonize host miRNAs to repress the expression of interferon-stimulated genes (ISGs) through sequence complementarity to sites located in their 3′ UTR [181]. Along the same line, miR-O7a is derived from the beginning of the coding sequence of the ORF7a transcript, which is the most abundant subgenomic viral RNA detected during SARS-CoV-2 infection [79]. Indeed, it was demonstrated that CoV2-miR-O7a associates with human
AGO proteins and that it can repress human targets [182]. Also, miR-nsp3-3p, a viral miRNA which was recently identified by Fu et al., exhibits comparable sensitivity, specificity, and precision to that of multiomics and could be used as a biomarker or a therapeutic target [183]. Liu et al. [107] found that a virus-encoded miRNA mir-147-3p could enhance the expression of TMPRSS2 with the function of strengthening SARS-CoV-2 infection in the gut; an antimiR could be constructed to inhibit the TMPRSS2 overexpression. Moreover, developing nanoformulations of the COVID-19-related miRNAs can overcome delivery limitations [60].

5. Conclusion and Future Perspectives

In this article, we reviewed the role of host and viral miRNAs during viral infection and disease development. It was reported that SARS-CoV-2 infection relies on epigenetic modulators of the host cell and the immune actors. We also suggested potential molecular mechanisms of miRNA therapy in treating COVID-19 disease based on published studies.

The study of microRNAome could help identify biomarkers of COVID-19, understand the viral infection and disease progression mechanisms, develop curative alternatives, and possibly help to relieve the long-haul symptoms in patients that recovered from SARS-CoV-2 infection. Targeting the host cellular miRNAs is challenging, and any modification may lead to side effects on organism, as these molecules have multigenic impact. However, targeting the highly conserved viral miRNAs seems to be an appropriate druggable target especially now when SARS-CoV-2 continue mutating. Although the biogenesis, mechanisms, and roles of viral miRNAs are not well determined, a considerable
advancement has been achieved due to the computational analysis and sequencing techniques. Future investigations will provide more evidence on miRNA approaches to fight COVID-19 and possibly other virus infection.

Abbreviations

ACE2: Angiotensin-converting enzyme 2
AGO: Argonaute
cDNA: Complementary DNA
COPD: Chronic obstructive pulmonary disease
COVID-19: Coronavirus disease 2019
CSF1: Macrophage colony-stimulating factor
CRISPR: Clustered regularly interspaced short palindromic repeats
IL: Interleukin
MERS-CoV: Middle East respiratory syndrome-CoV
MiPEP: miRNA-encoded peptide
miRNAs: MicroRNAs
mRNA: Messenger RNA
NSP3: Nonstructural protein 3
PDCD1: Programmed cell death protein 1
RBD: Receptor-binding domain
Ribozyme: Ribonucleic acid enzyme
RISC: RNA-induced silencing complex
RT-PCR: Real-time polymerase chain reaction
SARS-CoV: Severe acute respiratory syndrome-CoV
TGF: Transforming growth factor
TLR: Toll-like receptors
TMPRSS2: Transmembrane protease serine 2
TNF-α: Tumor necrosis factor-alpha
Treg: T regulatory cell
UTR: Untranslated region.

Conflicts of Interest

The authors confirm that there are no conflicts of interest.

Authors’ Contributions

Leyla Tahrani Hardin was responsible for original draft writing, conceptualization, reviewing, and editing. Nan Xiao was responsible for conceptualization, writing, reviewing, editing, and corresponding to the manuscript accuracy and verification. Both authors have agreed to the published version of the manuscript.

Acknowledgments

This work was supported by the Tobacco-Related Diseases Research Program Grant T30IP0917 from Regents of the University of California.

References

[1] R. Bartoszewski, M. Dabrowski, B. Jakiela et al., “SARS-CoV-2 may regulate cellular responses through depletion of specific host miRNAs,” American Journal of Physiology. Lung Cellular and Molecular Physiology, vol. 319, no. 3, pp. L444–L455, 2020.

[2] N. Durand, J. Mallea, and A. C. Zubair, “Insights into the use of mesenchymal stem cells in COVID-19 mediated acute respiratory failure,” Npj Regen Med., vol. 5, no. 1, pp. 1–9, 2020.

[3] S. Pulzele, B. Sahay, I. Yusufu et al., “COVID-19 virulence in aged patients might be impacted by the host cellular microRNAs abundance/profile,” Aging and Disease, vol. 11, no. 3, pp. 509–522, 2020.

[4] A. Remuzzi and G. Remuzzi, “COVID-19 and Italy: what next?,” The Lancet, vol. 395, no. 10231, pp. 1225–1228, 2020.

[5] N. Zhu, D. Zhang, W. Wang et al., “A novel coronavirus from patients with pneumonia in China, 2019,” The New England Journal of Medicine, vol. 382, no. 8, pp. 727–733, 2020.

[6] S. Nersisyan, N. Engibaryan, A. Gorbonos, K. Kirdey, A. Makhonin, and A. Tonevitsky, “Potential role of cellular miRNAs in coronavirus-host interplay,” PeerJ, vol. 8, p. e9994, 2020.

[7] Z. Xu, L. Shi, Y. Wang et al., “Pathological findings of COVID-19 associated with acute respiratory distress syndrome,” The Lancet Respiratory Medicine, vol. 8, no. 4, pp. 420–422, 2020.

[8] C. Wu, Y. Liu, Y. Yang et al., “Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods,” Acta Pharmacuetica Sinica B, vol. 10, no. 5, pp. 766–788, 2020.

[9] I. S. Mahmoud, Y. B. Jarrar, W. Alshaer, and S. Ismail, “SARS-CoV-2 entry in host cells-multiple targets for treatment and prevention,” Biochimie, vol. 175, pp. 93–98, 2020.

[10] I. Hamming, W. Timens, M. L. C. Bulthuis, A. T. Lely, G. J. Navis, and H. van Goor, “Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis,” The Journal of Pathology, vol. 203, no. 2, pp. 631–637, 2004.

[11] F. Qi, S. Qian, S. Zhang, and Z. Zhang, “Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses,” Biochemical and Biophysical Research Communications, vol. 526, no. 1, pp. 135–140, 2020.

[12] G. Ryu and H. W. Shin, “SARS-CoV-2 infection of airway epithelial cells,” Immune Netw., vol. 21, no. 1, 2021.

[13] Y. Deng, W. Liu, K. Liu et al., “Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study,” Chinese Medical Journal, vol. 133, no. 11, pp. 1261–1267, 2020.

[14] L. T. Hardin and N. Xiao, “Stem cells: a promising therapeutic target for COVID-19,” Stem Cell Discov., vol. 12, no. 1, pp. 720–726, 2022.

[15] A. Hussain, H. Rafeeq, H. M. Asif et al., “Current scenario of COVID-19 vaccinations and immune response along with antibody titer in vaccinated inhabitants of different countries,” International Immunopharmacology, vol. 99, article 108050, 2021.

[16] M. Ghildiyal and P. D. Zamore, “Small silencing RNAs: an expanding universe,” Nature Reviews. Genetics, vol. 10, no. 2, pp. 94–108, 2009.

[17] M. Ha and V. N. Kim, “Regulation of microRNA biogenesis,” Nature Reviews. Molecular Cell Biology, vol. 15, no. 8, pp. 509–524, 2014.

[18] R. S. Redis, S. Calin, Y. Yang, M. J. You, and G. A. Calin, “Cell-to-cell miRNA transfer: from body homeostasis to therapy,” Pharmacology & Therapeutics, vol. 136, no. 2, pp. 169–174, 2012.
H. K. Xu, L. J. Chen, S. N. Zhou, Y. F. Li, and C. Xiang, “Non-exosomal and exosomal circulatory miRNAs: which are more valid as biomarkers?,” *Frontiers in Pharmacology*, vol. 10, article 1500, 2020.

V. Ambros, “The functions of animal microRNAs,” *Nature*, vol. 431, no. 7006, pp. 350–355, 2004.

D. P. Bartel, “MicroRNAs: genomics, biogenesis, mechanism, and function,” *Cell*, vol. 116, no. 2, pp. 281–297, 2004.

N. Chauhan, M. Jaggi, S. C. Chauhan, and M. M. Yallapu, “COVID-19: fighting the invisible enemy with microRNAs,” *Expert Review of Anti-Infective Therapy*, vol. 19, no. 2, pp. 137–145, 2021.

C. E. Condrat, D. C. Thompson, M. G. Barbu et al., “miRNAs as biomarkers in disease: latest findings regarding their role in diagnosis and prognosis,” *Cell*, vol. 9, no. 2, p. 276, 2020.

T. Ma, Y. Chen, Y. Chen et al., “MicroRNA-132, delivered by mesenchymal stem cell-derived exosomes, promote angiogenesis in myocardial infarction,” *Stem Cells International*, vol. 2018, Article ID 3290372, 11 pages, 2018.

R. C. Friedman, K. H. Farh, C. B. Burge, and D. P. Bartel, “Most mammalian miRNAs are conserved targets of microRNAs,” *Genome Research*, vol. 19, no. 1, pp. 92–105, 2009.

W. Dunn, P. Trang, Q. Zhong, E. Yang, C. van Belle, and F. Liu, “Human cytomegalovirus expresses novel microRNAs during productive viral infection,” *Cellular Microbiology*, vol. 7, no. 11, pp. 1684–1695, 2005.

M. G. Hemida, X. Ye, S. Thair, and D. Yang, “Exploiting the therapeutic potential of microRNAs in viral diseases,” *Molecular Diagnosis & Therapy*, vol. 14, no. 5, pp. 271–282, 2010.

S. Omoto and Y. R. Fujii, “Regulation of human immunodeficiency virus 1 transcription by nef microRNA,” *The Journal of General Virology*, vol. 86, no. Part 3, pp. 751–755, 2005.

C. Qin, J. Wang, Q. Wei et al., “An animal model of SARS produced by infection of Macaca mulatta with SARS coronavirus,” *The Journal of Pathology*, vol. 206, no. 3, pp. 251–259, 2005.

V. Scaria, M. Harirhan, S. Maiti, B. Pillai, and S. K. Brahmachari, “Host-virus interaction: a new role for microRNAs,” *Retrovirology*, vol. 3, no. 1, p. 68, 2006.

S. Ura, M. Honda, T. Yamashita et al., “Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma,” *Hepatology*, vol. 49, no. 4, pp. 1098–1112, 2009.

P. T. I. Yee and C. L. Poh, “Development of novel miRNA-based vaccines and antivirals against Enterovirus 71,” *Current Pharmaceutical Design*, vol. 22, no. 44, pp. 6694–6700, 2016.

M. P. Dragomir, E. Knutsen, and G. A. Calin, “SnapShot: unconventional microRNA functions,” *Cell*, vol. 174, no. 4, pp. 1038–1038.e1, 2018.

R. F. Place, L. C. Li, D. Pookot, E. J. Noonan, and R. Dahiya, “MicroRNA-373 induces expression of genes with complementary promoter sequences,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 5, pp. 1608–1613, 2008.

M. Xiao, J. Li, W. Li et al., “MicroRNAs activate gene transcription epigenetically as an enhancer trigger,” *RNA Biology*, vol. 14, no. 10, pp. 1326–1334, 2017.

H. K. Xu, L. J. Chen, S. N. Zhou, Y. F. Li, and C. Xiang, “Multifunctional role of microRNAs in mesenchymal stem cell-derived exosomes in treatment of diseases,” *World J Stem Cells*, vol. 12, no. 11, pp. 1276–1294, 2020.

D. Lauressergues, J. M. Courzigou, H. S. Clemente et al., “Primary transcripts of microRNAs encode regulatory peptides,” *Nature*, vol. 520, no. 7545, pp. 90–93, 2015.

A. M. Eiring, J. G. Harb, P. Neviani et al., “miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts,” *Cell*, vol. 140, no. 5, pp. 652–665, 2010.

M. Fabbri, A. Paone, F. Calore et al., “MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response,” *Proceedings of the National Academy of Sciences*, vol. 109, no. 31, pp. E2110–E2116, 2012.

S. Vasudevan, Y. Tong, and J. A. Steitz, “Switching from repression to activation: microRNAs can up-regulate translation,” *Science*, vol. 318, no. 5858, pp. 1931–1934, 2007.

S. Das, M. Ferlito, O. A. Kent et al., “Nuclear miRNA regulates the mitochondrial genome in the heart,” *Circulation Research*, vol. 110, no. 12, pp. 1596–1603, 2012.

P. Li, J. Jiao, G. Gao, and B. S. Prabhakar, “Control of mitochondrial activity by miRNAs,” *Journal of Cellular Biochemistry*, vol. 113, no. 4, pp. 1104–1110, 2012.

M. Hill and N. Tran, “MicroRNAs regulating microRNAs in cancer,” *Trends Cancer*, vol. 4, no. 7, pp. 465–468, 2018.

A. Valinezhad Orang, R. Safaralizadeh, and M. Kazemzadeh-Bavili, “Mechanisms of miRNA-mediated gene regulation from common downregulation to mRNA-specific upregulation,” *Int J Genomics*, vol. 2014, article e970607, 2014.

G. Swaminathan, J. Martin-Garcia, and S. Navas-Martin, “RNA viruses and microRNAs: challenging discoveries for the 21st century,” *Physiological Genomics*, vol. 45, no. 22, pp. 1035–1048, 2013.

D. W. Trobaugh and W. B. Klimstra, “MicroRNA regulation of RNA virus replication and pathogenesis,” *Trends in Molecular Medicine*, vol. 23, no. 1, pp. 80–93, 2017.

R. Yan, Y. Zhang, Y. Li, L. Xia, Y. Guo, and Q. Zhou, “Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2,” *Science*, vol. 367, no. 6485, pp. 1444–1448, 2020.

M. Hoffmann, H. Kleine-Weber, S. Schroeder et al., “SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor,” *Cell*, vol. 181, no. 2, pp. 271–280.e8, 2020.

Y. Qiao, X. M. Wang, R. Mannan et al., “Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2,” *Proceedings of the National Academy of Sciences*, vol. 118, no. 1, 2021.

F. Hikmet, L. Méar, Å. Edvinsson, P. Micke, M. Uhlén, and C. Lindskog, “Mechanisms of miRNA-mediated gene regulation,” *Frontiers in Pharmacology*, vol. 11, no. 7, article e970607, 2014.

F. Hikmet, L. Méar, Å. Edvinsson, P. Micke, M. Uhlén, and C. Lindskog, “Mechanisms of miRNA-mediated gene regulation,” *Frontiers in Pharmacology*, vol. 11, no. 7, article e970607, 2014.
enzyme 2 is subject to post-transcriptional regulation by miR-421," Clinical Science, vol. 127, no. 4, pp. 243–249, 2014.

[54] J. R. Kemp, H. Unal, R. Desnoyer, H. Yue, A. Bhatnagar, and S. S. Karnik, "Angiotensin II-regulated microRNA 483-3p directly targets multiple components of the renin–angiotensin system," Journal of Molecular and Cellular Cardiology, vol. 75, pp. 25–39, 2014.

[55] L. J. Chen, R. Xu, H. M. Yu, Q. Chang, and J. C. Zhong, "The ACE2/Apolin signaling, microRNAs, and hypertension," International Journal of Hypertension, vol. 2015, Article ID e896861, 2015.

[56] T. Kaur, S. Kapila, R. Kapila et al., "Tmprss2 specific miRNAs as promising regulators for SARS-CoV-2 entry checkpoint," Virus Research, vol. 294, article ??, 2021.

[57] C. Hum, J. Loiselle, N. Ahmed, T. A. Shaw, C. Toudic, and A. Ivashchenko, A. Rakhmetullina, and D. Aisina, "miR-421, NAs can protect humans from coronaviruses COVID-19, SARS-CoV, and MERS-CoV, 2020. NAs can protect humans from coronaviruses COVID-19, SARS-CoV-2 genome: an in silico analysis," Non-Coding RNA Res., vol. 5, no. 4, pp. 222–231, 2020.

[58] C. Siniscalchi, A. Di Palo, A. Russo, and N. Potenza, "Human microRNAs interacting with SARS-CoV-2 RNA sequences: computational analysis and experimental target validation," Frontiers in Genetics, vol. 760, p. 12, 2021.

[59] Z. Zhang, C. Zhang, F. Li, B. Zhang, and Y. Zhang, "Regulation of memory CD8+ T cell differentiation by microRNAs," Cellular Physiology and Biochemistry, vol. 47, no. 6, pp. 2187–2198, 2018.

[60] E. Nepotchatykh, W. Elremaly, I. Caraus et al., "Profile of circulating microRNAs in myalgic encephalomyelitis and their relation to symptom severity, and disease pathophysiology," Scientific Reports, vol. 10, no. 1, p. 19660, 2020.

[61] H. Yousefi, A. Poursheikhani, Z. Bahmanpour et al., "SARS-CoV infection crosstalk with human host cell noncoding-RNA machinery: an in-silico approach," Biomed Pharmacother Biomedicine Pharmacother, vol. 130, article 110548, 2020.

[62] I. C. Schultz, A. P. S. Bertoni, and M. R. Wink, "Mesenchymal stem cell-derived extracellular vesicles carrying miRNA as a potential multi target therapy to COVID-19: an in silico analysis," Stem Cells Translational Medicine, vol. 9, pp. 341–356, 2021.

[63] A. Glopiaśka, M. Pawelczyk, and M. L. Kowalski, "MicroRNAs and the immune response to respiratory virus infections," Expert Review of Clinical Immunology, vol. 10, no. 7, pp. 963–971, 2014.

[64] M. Matsui, Y. Chu, H. Zhang et al., "Promoter RNA links transcriptional regulation of inflammatory pathway genes," Nucleic Acids Research, vol. 41, no. 22, pp. 10086–10109, 2013.

[65] C. Chakraborty, A. R. Sharma, G. Sharma, and S. S. Lee, "The interplay among microRNAs, major cytokines, and cancer-related inflammation," Molecular Therapy–Nucleic Acids, vol. 20, pp. 606–620, 2020.

[66] E. Wyler, K. Mösbauer, V. Franke et al., "Transcriptomic profiling of SARS-CoV-2 infected human cell lines identifies HSP90 as target for COVID-19 therapy," iScience, vol. 24, no. 3, article ??, 2021.

[67] A. Garg, B. Seeliger, A. A. Derda et al., "Circulating cardiovascular microRNAs in critically ill COVID-19 patients," European Journal of Heart Failure, vol. 23, no. 3, pp. 468–475, 2021.

[68] A. Badry, V. L. B. Jaspers, and C. A. Waugh, "Environmental pollutants modulate RNA and DNA virus-activated miRNA-155 expression and innate immune system responses: insights into new immunomodulatory mechanisms," Journal of Immunotoxicology, vol. 17, no. 1, pp. 86–93, 2020.

[69] L. Dickey, T. M. Hanley, T. B. Huffaker, A. G. Ramstead, R. M. O’Connell, and T. E. Lane, "MicroRNA 155 and viral-induced neuroinflammation," Journal of Neuroimmunology, vol. 308, pp. 17–24, 2017.

[70] A. Mehta and D. Baltimore, "MicroRNAs as regulatory elements in immune system logic," Nature Reviews. Immunology, vol. 16, no. 5, pp. 279–294, 2016.

[71] A. Gutierrez, C. H. de Azeredo Lima, R. L. Miranda, and M. R. Gadilha, "What is the potential function of microRNAs as
biomarkers and therapeutic targets in COVID-19?, “Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis., vol. 85, article 104417, 2020.

[85] B. Vastrad, C. Vastrad, and A. Tengli, “Identification of potential mRNA panels for severe acute respiratory syndrome coronavirus 2 (COVID-19) diagnosis and treatment using microarray dataset and bioinformatics methods,” 3 Biotech, vol. 10, no. 10, 2020.

[86] T. A. Taz, K. Ahmed, B. K. Paul et al., “Network-based identification genetic effect of SARS-CoV-2 infections to Idiopathic pulmonary fibrosis (IPF) patients,” Brief Bioinform. Published online October, vol. 7, 2021.

[87] J. H. Park, Y. Choi, C. W. Lim et al., “Potential therapeutic effect of micromas in extracellular vesicles from mesenchymal stem cells against SARS-CoV-2,” Cell, vol. 10, no. 9, p. 2393, 2021.

[88] K. J. Gordon and G. C. Blobe, “Superfamily signaling pathways in human disease,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1782, no. 4, pp. 197–228, 2008.

[89] H. Henzinger, D. A. Barth, C. Klec, and M. Pichler, “Non-coding RNAs and SARS-related coronaviruses,” Viruses, vol. 12, p. 12, 2020.

[90] Z. Ghosh, B. Mallick, and J. Chakrabarti, “Cellular versus viral microRNAs in host-virus interaction,” Nucleic Acids Research, vol. 37, no. 4, pp. 1035–1048, 2009.

[91] P. Bruscella, S. Bottini, C. Baudesson, J. M. Pawlotsky, C. Feray, and C. Trubucchi, “Viruses and miRNAs: more friends than foes,” Frontiers in Microbiology, vol. 8, p. 8, 2017.

[92] J. Duy, A. N. Honko, L. A. Altamura et al., “Virus-encoded miRNAs in Ebola virus disease,” Scientific Reports, vol. 8, no. 1, p. ??, 2018.

[93] A. Grundhoff and C. S. Sullivan, “Virus-encoded microRNAs,” Virology, vol. 411, no. 2, pp. 325–343, 2011.

[94] H. Liang, K. Zhen, J. Zhang, C. Y. Zhang, and X. Chen, “New roles for microRNAs in cross-species communication,” RNA Biology, vol. 10, no. 3, pp. 367–370, 2013.

[95] V. Verma, A. Dwivedi, N. Kumar, and B. K. Biswal, “Implications of the virus-encoded miRNA and host miRNA in the pathogenicity of SARS-CoV-2,” https://arxiv.org/abs/2004.04874, 2020.

[96] J. Lei, Y. Kusov, and R. Hilgenfeld, “Nsp3 of coronaviruses: structures and functions of a large multi-domain protein,” Antiviral Research, vol. 149, pp. 58–74, 2018.

[97] L. van Dorp, D. Richard, C. C. S. Tan, L. P. Shaw, M. Acman, and F. Balloux, “No evidence for increased transmissibility from recurrent mutations in SARS-CoV-2,” Nature Communications, vol. 11, no. 1, p. 5986, 2020.

[98] A. Hosseini Rad Sm and A. D. McLellan, “Implications of SARS-CoV-2 mutations for genomic RNA structure and host microRNA targeting,” International Journal of Molecular Sciences, vol. 21, no. 13, 2020.

[99] L. Chen, C. Li, Z. Peng, J. Zhao, G. Gong, and D. Tan, “miR-197 expression in peripheral blood mononuclear cells from hepatitis B virus-infected patients,” Gut Liver., vol. 7, no. 3, pp. 335–342, 2013.

[100] P. Peng, J. He, J. F. C. Loo, S. K. Kong, B. Li, and D. Gu, “Identification of serum microRNAs as diagnostic biomarkers for influenza H7N9 infection,” Virol Rep., vol. 7, pp. 1–8, 2020.

[101] H. Wang, X. Su, M. Yang et al., “Reciprocal control of miR-197 and IL-6/STAT3 pathway reveals miR-197 as potential therapeutic target for hepatocellular carcinoma,” Oncolimmunology., vol. 4, no. 10, article e1031440, 2015.

[102] A. P. Chan, Y. Choi, and N. J. Schork, “Conserved genomic terminals of SARS-CoV-2 as coevolving functional elements and potential therapeutic targets,” mSphere., vol. 5, no. 6, 2020.

[103] J. H. Park, Y. Choi, C. W. Lim et al., “Antiviral effects of miRNAs in extracellular vesicles against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and mutations in SARS-CoV-2 RNA virus,” bioRxiv. Published online July 27, 2020: 2020.07.27.190561.

[104] J. Haasnoot, W. de Vries, E. J. Geuithje, M. Prins, P. de Haan, and B. Berkhou, “The Ebola virus VP35 protein is a suppressor of RNA silencing. Kaawaoka Y, ed,” PLoS Pathogens, vol. 3, no. 6, p. e866, 2007.

[105] Y. Wang, N. Kato, A. Jazag et al., “Hepatitis C virus core protein is a potent inhibitor of RNA silencing-based antiviral response,” Gastroenterology, vol. 130, no. 3, pp. 883–892, 2006.

[106] L. Feng, C. G. Duan, and H. S. Guo, “Inhibition of in vivo Slicer activity of Argonaute protein 1 by the viral 2b protein...
independent of its dsRNA-binding function,” *Molecular Plant Pathology*, vol. 14, no. 6, pp. 617–622, 2013.

[119] L. Lakatos, T. Csorba, V. Pantaleo et al., “Small RNA binding is a common strategy to suppress RNA silencing by several viral suppressors,” *The EMBO Journal*, vol. 25, no. 12, pp. 2768–2780, 2006.

[120] Y. K. Kim, B. Kim, and V. N. Kim, “Re-evaluation of the roles of DROSHA, Exportin 5, and Dicer in microRNA biogenesis,” *Proceedings of the National Academy of Sciences*, vol. 113, no. 13, pp. E1881–E1889, 2016.

[121] S. L. Moon, B. J. T. Dodd, D. E. Brackney, C. J. Wilusz, G. D. Ebel, and J. Wilusz, “Flavivirus sRNA suppresses antiviral RNA interference in cultured cells and mosquitoes and directly interacts with the RNAi machinery,” *Virology*, vol. 485, pp. 322–329, 2015.

[122] S. Arora, P. Singh, R. Dohare, R. Jha, and S. M. Ali, “Unraveling host-pathogen interactions: ceRNA network in SARS-CoV-2 infection (COVID-19),” *Gene*, vol. 762, article 145057, 2020.

[123] G. Neumann, G. G. Brownlee, E. Fodor, and Y. Kawaoka, “Orthomyxovirus replication, transcription, and polyadenylation,” in *Biology of Negative Strand RNA Viruses: The Power of Reverse Genetics. Current Topics in Microbiology and Immunology*, Y. Kawaoka, Ed., pp. 121–143, Springer, 2004.

[124] M. Calderon-Dominguez, E. Trejo-Gutierrez, A. Gonzalez-Rovira et al., “Serum microRNAs targeting ACE2 and RAB14 genes distinguish asymptomatic from critical COVID-19 patients,” *Molecular Therapy–Nucleic Acids*, vol. 29, pp. 76–87, 2022.

[125] M. Panda, E. Kalita, S. Singh, K. Kumar, A. Rao, and V. K. Prajapati, “miRNA-SARS-CoV-2 dialogue and prospective anti-COVID-19 therapies,” *Life Sciences*, vol. 305, article 120761, 2022.

[126] S. Khadke, N. Ahmed, N. Ahmed et al., “Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents,” *Virology Journal*, vol. 17, no. 1, p. 154, 2020.

[127] L. D. Rizkita and I. Astuti, “The potential of miRNA-based therapeutics in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A review,” *Journal of Pharmaceutical Analysis*, vol. 11, pp. 265–271, 2021.

[128] C. Li, X. Hu, L. Li, J. Li, and J. Li, “Differential microRNA expression in the peripheral blood from human patients with COVID-19,” *Journal of Clinical Laboratory Analysis*, vol. 34, no. 10, article e23590, 2020.

[129] J. Shi, X. Ma, Y. Su et al., “MiR-31 mediates inflammatory signaling to promote re-epithelialization during skin wound healing,” *The Journal of Investigative Dermatology*, vol. 138, no. 10, pp. 2253–2263, 2018.

[130] Y. Tian, J. Xu, Y. Li et al., “MicroRNA-31 reduces inflammatory signaling and promotes regeneration in colon epithelium, and delivery of mimics in microspheres reduces colitis in mice,” *Gastroenterology*, vol. 156, no. 8, pp. 2281–2296.e6, 2019.

[131] R. J. Farr, C. L. Roots, L. C. Rowntree et al., “Altered microRNA expression in COVID-19 patients enables identification of SARS-CoV-2 infection,” *PLoS Pathogens*, vol. 17, no. 7, article e009759, 2021.

[132] M. A. A. Khan and A. B. M. M. K. Islam, “SARS-CoV-2 proteins exploit host’s genetic and epigenetic mediators for the annexation of key host signaling pathways that confers its immune evasion and disease pathophysiology,” bioRxiv. Published online May 8, 2020: 2020.05.06.050260.

[133] A. L. Ellis-Connell, T. Iempridee, I. Xu, and J. E. Mertz, “Cellular microRNAs 200b and 429 regulate the Epstein-Barr virus switch between latency and lytic replication,” *Journal of Virology*, vol. 84, no. 19, pp. 10329–10343, 2010.

[134] Z. Liu, J. Wang, Y. Ge et al., “SARS-CoV-2 encoded microRNAs are involved in the process of virus infection and host immune response,” *Journal of Biomedical Research*, vol. 35, no. 3, pp. 216–227, 2021.

[135] C. Raman, C. Ren, S. Boas et al., “TCR signaling strength dependent regulation of T cell proliferation, survival and Th differentiation by TGF-βR3 (betaglyc),” *Journal of Immunology*, vol. 198, 1 Supplement, p. 201.8, 2017.

[136] R. Satyam, T. Bhardwaj, S. Goel et al., “miRNAs in SARS-CoV-2: a spoke in the wheel of pathogenesis,” *Current Pharmaceutical Design*, vol. 27, no. 13, pp. 1628–1641, 2021.

[137] A. Zhai, J. Qian, W. Kao et al., “Borna disease virus encoded phosphoprotein inhibits host innate immunity by regulating miR-155,” *Antiviral Research*, vol. 98, no. 1, pp. 66–75, 2013.

[138] D. K. Soni, J. Cabrera-Luque, S. Kar, C. Sen, J. Devaney, and R. Biswas, “Suppression of MiR-155 attenuates lung cytokine storm induced by SARS-CoV-2 infection in human ACE2-transgenic mice,” *Immunology*, 2020.

[139] T. Donyavi, F. Bokharaei-Salim, H. B. Baghi et al., “Acute and post-acute phase of COVID-19: Analyzing expression patterns of miRNA-29a-3p, 146a-3p, 155-5p, and let-7b-3p in PBMC,” *International Immunopharmacology*, vol. 97, article 107641, 2021.

[140] H. Tang, Y. Gao, Z. Li et al., “The noncoding and coding transcriptional landscape of the peripheral immune response in patients with COVID-19,” *Clinical and Translational Medicine*, vol. 10, no. 6, article e200, 2020.

[141] S. Nersisyan, N. Engibaryan, A. Kirdey, A. Makhonin, and A. Tonevitsky, “The potential role of MiR-21-3p in coronavirus-host interplay,” *Bioinformatics*, 2020.

[142] D. W. Trobaugh, C. L. Gardner, C. Sun et al., “RNA viruses can hijack vertebrate microRNAs to suppress innate immunity,” *Nature*, vol. 506, no. 7487, pp. 245–248, 2014.

[143] R. W. Lung, J. H. Tong, Y. M. Sung et al., “Modulation of LMP2A expression by a newly identified Epstein-Barr virus-encoded microRNA miR-BART22,” *Neoplasia N Y N.*, vol. 11, no. 11, pp. 1174–1184, 2009.

[144] S. A. Dingsdag, O. K. Clay, and G. A. Quintero, “COVID-19 severity, miR-21 targets, and common human genetic variation. Letter regarding the article Circulating cardiovascular microRNAs in critically ill COVID-19 patients,” *European Journal of Heart Failure*, vol. 23, no. 11, pp. 1986–1987, 2021.

[145] B. Bautista-Becerril, G. Pérez-Dimas, P. C. Sommerhalder-Nava et al., “miRNAs, from evolutionary junk to possible prognostic markers and therapeutic targets in COVID-19,” *Viruses*, vol. 14, no. 1, p. 41, 2021.

[146] M. Mukherjee and S. Goswami, “Modulation of genome stability in SARS-CoV-2,” *Genomics*, vol. 17, no. 3, pp. 216–227, 2021.

[147] C. Yin, “Genotyping coronavirus SARS-CoV-2: methods and implications,” *Genomics*, vol. 112, no. 5, pp. 3588–3596, 2020.
D. P. Bartel, “MicroRNAs: target recognition and regulatory functions,” Cell, vol. 136, no. 2, pp. 215–233, 2009.

R. P. Kincaid, J. M. Burke, and C. S. Sullivan, “RNA virus microRNA that mimics a B-cell oncomiR,” Proceedings of the National Academy of Sciences, vol. 109, no. 8, pp. 3077–3082, 2012.

E. Gottwein, N. Mukherjee, C. Sachse et al., “A viral microRNA functions as an orthologue of cellular miR-155,” Nature, vol. 450, no. 7172, pp. 1096–1099, 2007.

R. L. Skalsky, M. A. Samols, K. B. Plaisance et al., “Kaposi’s sarcoma-associated herpesvirus encodes an ortholog of miR-155,” Journal of Virology, vol. 81, no. 23, pp. 12836–12845, 2007.

S. Kim, E. Lee, J. Jung et al., “MiR-155 positively regulates glucose metabolism via PIK3R1-FOXO3a-βMYC axis in breast cancer,” Oncogene, vol. 37, no. 22, pp. 2982–2991, 2018.

S. Mattiske, R. J. Suetani, P. M. Neilsen, and D. F. Callen, “The oncogenic role of miR-155 in breast cancer,” Cancer Epidemiol Prev Biomark., vol. 21, no. 8, pp. 1236–1243, 2012.

P. Zhang, K. Bill, J. Liu et al., “MiR-155 is a liposarcoma oncogene that targets casein kinase-1α and enhances β-catenin signaling.” Cancer Research, vol. 72, no. 7, pp. 1751–1762, 2012.

D. Baltimore, M. P. Boldin, R. M. O’Connell, D. S. Rao, and K. D. Taganov, “MicroRNAs: new regulators of immune cell development and function,” Nature Immunology, vol. 9, no. 8, pp. 839–845, 2008.

L. M. Das, M. D. L. A. Torres-Castillo, T. Gill, and A. D. Levine, “TGF-β conditions intestinal T cells to express increased levels of miR-155, associated with down-regulation of IL-2 and ifk mRNA,” Mucosal Immunology, vol. 6, no. 1, pp. 167–176, 2013.

D. T. Gracias, E. Stekleati, J. L. Hope et al., “The microRNA miR-155 controls CD8(+) T cell responses by regulating interferon signaling,” Nature Immunology, vol. 14, no. 6, pp. 593–602, 2013.

E. Vigorito, S. Kohlihaas, D. Lu, and R. Leyland, “miR-155: an ancient regulator of the immune system,” Immunological Reviews, vol. 253, no. 1, pp. 146–157, 2013.

J. Wang, K. Li, X. Zhang et al., “MicroRNA-155 controls iNKT cell development and lineage differentiation by coordinating multiple regulating pathways,” Frontiers in Cell and Development Biology, vol. 8, p. 1676, 2021.

D. Cazalla, T. Yario, and J. A. Steitz, “Down-regulation of a host microRNA by a herpesvirus saimiri noncoding RNA,” Science, vol. 328, no. 5985, pp. 1563–1566, 2010.

M. de la Mata, D. Gaidatzis, M. Vitanescu et al., “Potent degradation of neuronal miRNAs induced by highly complementary targets,” EMBO Reports, vol. 16, no. 4, pp. 500–511, 2015.

F. Fuchs Wightman, L. E. Gionio, J. P. Fededa, and M. de la Mata, “Target RNAs strike back on microRNAs,” Frontiers in Genetics, vol. 9, 2018.

B. Xia, J. Lu, R. Wang, Z. Yang, X. Zhou, and P. Huang, “miR-21-3p regulates influenza A virus replication by targeting histone deacetylase-8,” Frontiers in Cellular and Infection Microbiology, vol. 8, p. 175, 2018.

S. Kim, E. Lee, J. Jung et al., “MiR-155 controls CD8(+) T cell responses by regulating increased levels of miR-155, associated with down-regulation of interferon signaling,” Nature Immunology, vol. 14, no. 6, pp. 198–201, 2010.

M. Wang, B. Gu, X. Chen, Y. Wang, P. Li, and K. Wang, “The function and therapeutic potential of Epstein-Barr virus-encoded microRNAs in cancer,” Molecular Therapy-Nucleic Acids, vol. 17, pp. 657–668, 2019.

B. C. Bernardo, P. Gregorevic, J. R. McMul-len, “Generation of microRNA-34 sponges and tough decoys for the heart: developments and challenges,” Frontiers in Pharmacology, vol. 9, p. 1090, 2018.

H. Suryawanshi, V. Scaria, and S. Maiti, “Modulation of microRNA function by synthetic ribozymes,” Molecular Bi-Systems, vol. 6, no. 10, pp. 1807–1809, 2010.

H. Chang, B. Yi, R. Ma, X. Zhang, H. Zhao, and Y. Xi, “CRISPR/cas9, a novel genomic tool to knock down microRNA in vitro and in vivo,” Scientific Reports, vol. 6, no. 1, p. 22312, 2016.

L. Lataniotis, A. Albrecht, F. O. Kok et al., “CRISPR/Cas9 editing reveals novel mechanisms of clustered microRNA regulation and function,” Scientific Reports, vol. 7, no. 1, p. 8585, 2017.

Z. Zhang, R. Ursin, S. Mahapatra, and G. I. Gallicano, “CRISPR/CAS9 ablation of individual miRNAs from a miRNA family reveals their individual efficacies for regulating cardiac differentiation,” Mechanisms of Development, vol. 150, pp. 10–20, 2018.

H. Bi, Q. Fei, R. Li et al., “Disruption of miRNA sequences by TALENs and CRISPR/Cas9 induces varied lengths of miRNA production,” Plant Biotechnology Journal, vol. 18, no. 7, pp. 1526–1536, 2020.
MicroRNA (miRNA) plays a crucial role in regulating gene expression by binding to the 3′ untranslated region (3′ UTR) of messenger RNA (mRNA), silencing the expression of target genes. In the context of COVID-19, miRNAs have been extensively studied for their potential as diagnostic and therapeutic targets. Several miRNAs have been identified as differentially expressed in serum, lung, and other tissues of COVID-19 patients, providing insights into the pathophysiological mechanisms driving the disease.

For instance, a study by R. Keikha, S. M. Hashemi-Shahri, and A. Jebali, published in Cell Discovery, found that miR-31, miR-29, miR-126, and miR-17 and their mRNA targets in the serum of COVID-19 patients with different grades during hospitalization, help protect against acute respiratory distress syndrome by targeting p65, as reported in Bioinformatics-based identification. This study, published in 2020, highlights the role of miR-146a in decreasing serum levels of the inflammasome marker miR-146a, associated with clinical non-response to tocilizumab in COVID-19 patients, as mentioned in Mechanisms of Ageing and Development. X. Deng, Z. Lin, C. Zhu, and Y. Fu, in Open Life Sciences, found that upregulation of miR-150-5p alleviates LPS-induced inflammatory response and apoptosis of RAW264.7 macrophages by targeting Notch1.

Other studies have explored the role of miRNAs in the prenatal and postnatal stages of COVID-19. A study by Y. Lin, W. Deng, J. Pang et al., titled “The microRNA-99 family modulates hepatitis B virus replication by promoting IGF-1R/P38/ Akt/mTOR/ULK1 signaling-induced autophagy,” published in Cellular Microbiology, vol. 19, no. 5, article e12709, 2017, investigated the role of microRNAs in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

In the context of chronic obstructive pulmonary disease (COPD), miR-195 inhibits macrophages to protect against acute respiratory distress syndrome by targeting the β/BAMBI pathway, as reported in Current Biology. The emerging role of miRNAs in extracellular vesicles against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and mutations in SARS-CoV-2 RNA virus, as mentioned in Molecular Biology, 2020, has also been highlighted.

These findings underscore the potential of miRNAs as biomarkers for the diagnosis and severity of COVID-19, offering hope for the development of new diagnostic tools and therapeutic strategies to combat the disease.
[210] R. P. Duicker, E. H. Adam, S. Wirtz et al., “The MiR-320 family is strongly downregulated in patients with COVID-19 induced severe respiratory failure,” International Journal of Molecular Sciences, vol. 22, no. 19, p. 10351, 2021.

[211] Y. Wei, M. Nazari-Jahantigh, L. Chan et al., “The microRNA-342-5p fosters inflammatory macrophage activation through an Akt1- and microRNA-155-dependent pathway during atherosclerosis,” Circulation, vol. 127, no. 15, pp. 1609–1619, 2013.

[212] H. S. Yuan, D. Q. Xiong, F. Huang, J. Cui, and H. Luo, “MicroRNA-421 inhibition alleviates bronchopulmonary dysplasia in a mouse model via targeting Fgf10,” Journal of Cellular Biochemistry, vol. 120, no. 10, pp. 16876–16887, 2019.

[213] S. Ahmad, S. Manzoor, S. Siddiqui et al., “Epigenetic underpinnings of inflammation: connecting the dots between pulmonary diseases, lung cancer and COVID-19,” Seminars in Cancer Biology, 2022.

[214] W. Niu, F. Wu, H. Cui et al., “Network pharmacology analysis to identify phytochemicals in traditional Chinese medicines that may regulate ACE2 for the treatment of COVID-19,” Evidence-based Complementary and Alternative Medicine, vol. 2020, Article ID e7493281, 14 pages, 2020.

[215] N. Arghiani, T. Nissan, and M. M. Matin, “Role of microRNAs in COVID-19 with implications for therapeutics,” Biomedicine & Pharmacotherapy, vol. 144, article 112247, 2021.

[216] L. Pasquali, MiR-1307 is upregulated in psoriasis keratinocytes and promotes keratinocyte inflammatory response, Proceedings of the 49th Annual ESDR Meeting, Bordeaux, France, 2017.